(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
18 May 2012 (18.05.2012)

PCT

(10) International Publication Number
WO 2012/062713 A1

(51) **International Patent Classification**:
C07K 16/28 (2006.01)

(21) **International Application Number**:
PCT/EP2011/069571

(22) **International Filing Date**:
7 November 2011 (07.11.2011)

(25) **Filing Language**: English

(26) **Publication Language**: English

(30) **Priority Data**:
61/411,083 8 November 2010 (08.11.2010) US

(71) **Applicant** *(for all designated States except US)*: **NOVARTIS AG** [CH/CH]; Lichtstrasse 35, CH-4056 Basel (CH).

(72) **Inventors; and**

(75) **Inventors/Applicants** *(for US only)*: **BRADLEY, Michelle** [GB/GB]; Novartis Pharmaceuticals UK Limited, Wimblehurst Road, Horsham, West Sussex Sussex RH12 5AB (GB). **BROWN, Zarin** [GB/GB]; Novartis Pharmaceuticals UK Limited, Wimblehurst Road, Horsham, West Sussex Sussex RH12 5AB (GB). **CHARLTON, Steven John** [GB/GB]; Novartis Pharmaceuticals UK Limited, Wimblehurst Road, Horsham, West Sussex Sussex RH12 5AB (GB). **CROMIE, Karen** [GB/BE]; Ablynx NV, Technologiepark 21, B-9052 Zwijnaarde (BE). **DOMBRECHT, Bruno** [BE/BE]; Ablynx NV, Technologiepark 21, B-9052 Zwijnaarde (BE). **STEFFENSEN, Soren** [DK/BE]; Ablynx NV, Technologiepark 21, B-9052 Zwijnaarde (BE). **VAN HEEKE, Gino** [BE/GB]; Novartis Pharmaceuticals UK Limited, Wimblehurst Road, Horsham, West Sussex Sussex RH12 5AB (GB).

(74) **Agents**: **KASSOW, Anders** et al.; Novartis Pharma Ag, Patent Department, CH-4002 Basel (CH).

(81) **Designated States** *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) **Designated States** *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

Published:

— *with international search report (Art. 21(3))*

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

WO 2012/062713 A1

(54) **Title**: CXCR2 BINDING POLYPEPTIDES

(57) **Abstract**: The present invention relates to polypeptides directed against or specifically binding to chemokine receptor CXCR2 and in particular to polypeptides capable of modulating signal transduction from CXCR2. The invention also relates to nucleic acids, vectors and host cells capable of expressing the polypeptides of the invention, pharmaceutical compositions comprising the polypeptides and uses of said polypeptides and compositions for treatment of diseases involving aberrant functioning of CXCR2.